5 results
The study will compare the overall survival (OS) between the MABp1 treated and placebo arms. Secondary endpoints will include change in lean body mass from screening to the cycle 5 assessment and change in quality of life.
To demonstrate that the infliximab serum concentration of Remsima* is non-inferior to the infliximab serum concentration of Remicade , 16 weeks after switch from Remicade to Remsima* in subjects with CD, UC or RA in stable remission for > 30…
This study aims to validate the Corsano CardioWatch 287-2 for the continuous monitoring of heart rate at <= 4 bpm root mean squared error (RMSE); interbeat intervals at <= 50 ms RMSE; breathing rate at <= 2 brpm RMSE; and…
Primary objective: To compare the number of episodes of atrial fibrillation detected by the Corsano CardioWatch 287-2 during 28 days of use with the number of episodes of atrial fibrillation detected by conventional Holter monitoring during 48 hours…
This study aims to evaluate the Corsano Cardiowatch 287-2 for heart rate, heart rate variability (RR intervals), oxygen saturation, respiratory rate, and blood pressure during strenuous activities such as High-Intensity Interval Training (HIIT).…